Resmonics, founded in October 2020, is developing digital biomarkers based on state-of-the-art mobile sensing technology to enable respiratory disease monitoring among patients with asthma or COPD (Chronic obstructive pulmonary disease). Its first product, Asthma Guardian, turns a patient’s smartphone into a guardian angel at night, protecting them from life-threatening asthma attacks, and it helps them to stay in control of their disease.
The company builds on the research its two founders conducted at the CSS Health Lab, a joint collaboration of ETH Zurich, University St. Gallen, and CSS Insurance, one of the leading players in the Swiss healthcare market.
CSS Insurance is now investing in the company to further product development and enter the Swiss and European market in Q3/21. The company will also seek certification to recognize its solution as a medical device.
In return for its investment, CSS Insurance will take a minority stake in Resmonics. Both parties set up the deal with the goal of facilitating Resmonics' long-term growth by remaining an attractive investment opportunity for new investors in future fundraising rounds.
“We are very excited to have attracted CSS Insurance as our first investor,” says Peter Tinschert, CEO and Co-Founder of Resmonics. “Their profound understanding of the evolving digital health market and strong network puts us in a unique position to grow Resmonics beyond the Swiss market.”
Peter Mittemeyer, Head of Strategy & Corporate Services, Member of the Corporate Executive Committee at CSS Insurance, points out that despite the early stage of Resmonics, CSS is confident about Resmonics’ future success: “Due to our involvement in the CSS Health Lab, we were able to follow the Resmonics’ founding team closely for a couple of years now.” He adds, “Resmonics has developed an innovative and fully scalable technology for addressing a global health challenge – the management of chronic respiratory diseases.”